Biotech RadarJobs updated

COMPANY

Glaukos

HQ: Aliso Viejo, CA source · glaukos.com ↗

FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3

44 open jobs · last seen Oct 23, 2026 · 52 sources

Keywords: eye diseases glaucoma retinal disease Keratoconus Open-Angle Glaucoma Ocular Hypertension Progressive Keratoconus Primary Open-Angle Glaucoma Primary Open Angle Glaucoma Open Angle Glaucoma Demodex Blepharitis Phacoemulsification Cataract Surgery Persistent Corneal Epithelial Defect Corneal Persistent Epithelial Defect Corneal Ectasia Glaucoma Open-angle Presbyopia Dry Eye Disease Kerato Conjunctivitis Sicca Ectasia Myopia Travoprost Vedera KXS GLK-221 iDose TR Corneal Collagen Cross-linking iStent Infinite

Location: Aliso Viejo, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

44Open jobs67Trials (company is sponsor)2FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Clinical Research Associate - Multiple Levels AvailableUnited StatesOct 22, 2026Oct 23, 2026
Regional Business Manager - BrazilBrazilOct 16, 2026Oct 16, 2026
Sr. Applied Research EngineerBurlington, MA, United StatesOct 16, 2026Oct 18, 2026
Glaucoma Reimbursement LiaisonAtlanta, GA, United StatesOct 15, 2026Oct 16, 2026
Business Systems Manager-QualityAliso Viejo, CA, United StatesOct 14, 2026Oct 16, 2026

See all 44 jobs

Timeline

  1. Trial start —: iDose TR Administration in an Office-Based Surgery Setting source ↗
  2. Trial start Phase 4: Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus source ↗
  3. Trial start Phase 3: Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant source ↗
  4. FDA FDA New indication / efficacy supplement: IDOSE TR (travoprost) — NDA218010/4, Jan 27, 2026. Applicant at approval: Glaukos Corporation. source ↗
  5. Trial start Phase 2: Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus source ↗
  6. Trial start —: Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg source ↗
  7. Trial start Phase 2: Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis source ↗
  8. FDA FDA Original approval: EPIOXA HD/EPIOXA KIT (riboflavin 5'-phosphate sodium) — NDA219910, Oct 17, 2025. Applicant at approval: Glaukos Corporation. source ↗
  9. Trial start 2: Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant source ↗
  10. Trial start Phase 4: Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone source ↗
  11. Trial start Phase 2: Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension source ↗
  12. Trial start Phase 4: Travoprost Intraocular Implant + iStent Infinite source ↗
  13. Trial start Phase 3: Travoprost Intraocular Implant in Conjunction With Cataract Surgery source ↗
  14. Trial start Not phased (device or behavioral study): Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma source ↗
  15. Trial start Phase 2: A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED source ↗
  16. Trial start Phase 1/Phase 2: Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus source ↗
  17. Trial start Phase 2: Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia source ↗
  18. Trial start Phase 2: Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease source ↗
  19. Trial start Not phased (device or behavioral study): Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor source ↗
  20. Trial start Phase 2: Performance of the Travoprost Intraocular Implant source ↗
  21. Trial start Phase 2: Study of Exchange of Travoprost Intraocular Implant source ↗
  22. Trial start Not phased (device or behavioral study): iStent Inject New Enrollment Post-Approval Study source ↗
  23. Trial start Phase 2: NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries source ↗
  24. Trial start —: iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study source ↗
  25. Trial start Phase 3: Clinical Study Comparing Two Models of a Travoprost Intraocular Implant source ↗

Showing 25 of 52 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) Showing 50 of 67

RecordTitlePhaseStatusStartPrimary completion
NCT07816692iDose TR Administration in an Office-Based Surgery SettingNot listedRecruitingMay 13, 20262027-03 (estimated)
NCT07075718Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant2RecruitingJun 12, 20252028-03 (estimated)
NCT07629557Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for KeratoconusPhase 4RecruitingMay 11, 20262027-09 (estimated)
NCT06066645Travoprost Intraocular Implant + iStent InfinitePhase 4RecruitingSep 14, 20232027-05 (estimated)
NCT07495852Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantPhase 3RecruitingFeb 17, 20262028-06 (estimated)
NCT07400926Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcgNot listedRecruitingDec 17, 20252026-06 (estimated)
NCT07400965Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisPhase 2RecruitingDec 5, 20252026-09 (estimated)
NCT07400952Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With KeratoconusPhase 2RecruitingDec 23, 20252027-04 (estimated)
NCT06848946Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery AlonePhase 4RecruitingJan 13, 20252026-08 (estimated)
NCT05966493A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCEDPhase 2RecruitingAug 17, 20232025-12 (estimated)
NCT04081103NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular InjuriesPhase 2TerminatedJun 30, 2020Feb 7, 2022 (actual)
NCT03868124Clinical Study Comparing Two Models of a Travoprost Intraocular ImplantPhase 3CompletedSep 17, 2018Jun 10, 2022 (actual)
NCT03519386Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%Phase 3CompletedJul 26, 2018Apr 5, 2022 (actual)
NCT06582732Performance of the Travoprost Intraocular ImplantPhase 2CompletedMar 10, 2021Nov 2, 2023 (actual)
NCT05127551Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. CompetitorNot phased (device or behavioral study)Unknown status (ClinicalTrials.gov)Nov 27, 2021Feb 29, 2024 (actual)
NCT05314738Safety and Efficacy of Corneal Cross-linking in Subjects With KeratoconusPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Mar 8, 20222025-08 (estimated)
NCT06061718Travoprost Intraocular Implant in Conjunction With Cataract SurgeryPhase 3Unknown status (ClinicalTrials.gov)Sep 11, 2023Mar 18, 2024 (actual)
NCT03319082Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive SurgeryNot listedUnknown status (ClinicalTrials.gov)Oct 4, 20172026-02 (estimated)
NCT04624698iStent Inject New Enrollment Post-Approval StudyNot phased (device or behavioral study)Unknown status (ClinicalTrials.gov)Sep 22, 20202026-05 (estimated)
NCT03442751Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive KeratoconusPhase 3CompletedApr 6, 2018Nov 1, 2019 (actual)
NCT06152861Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular HypertensionPhase 2Unknown status (ClinicalTrials.gov)Nov 15, 20232024-08 (estimated)
NCT06057051Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle GlaucomaNot phased (device or behavioral study)RecruitingSep 1, 20232025-08 (estimated)
NCT04615403Study of Exchange of Travoprost Intraocular ImplantPhase 2CompletedNov 19, 2020Feb 28, 2022 (actual)
NCT02754596Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic SolutionPhase 2CompletedMar 29, 2016Aug 1, 2017 (actual)
NCT05124275Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of PresbyopiaPhase 2CompletedJan 3, 2022Sep 6, 2022 (actual)
NCT05119920Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye DiseasePhase 2CompletedJan 3, 2022Jul 27, 2022 (actual)
NCT02327312Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser TrabeculoplastyNot phased (device or behavioral study)TerminatedDec 16, 2014May 31, 2019 (actual)
NCT03255785Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent SupraNot phased (device or behavioral study)CompletedMay 1, 2018Dec 3, 2019 (actual)
NCT03478293iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive MedicationsNot phased (device or behavioral study)TerminatedFeb 27, 2018Dec 30, 2020 (actual)
NCT03255798A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent SupraNot phased (device or behavioral study)TerminatedAug 1, 2017Jun 6, 2019 (actual)
NCT02868190Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive MedicationPhase 4Completed2013-03Nov 8, 2019 (actual)
NCT01444040Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or TravoprostPhase 4Completed2011-09Mar 28, 2019 (actual)
NCT01456390Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass StentsNot phased (device or behavioral study)Completed2011-09Mar 26, 2019 (actual)
NCT01252914A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal StentPhase 4Completed2010-12Dec 16, 2019 (actual)
NCT01252888Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStentsPhase 4Completed2010-122016-07 (actual)
NCT02873806Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive AgentsPhase 4Completed2013-03Nov 8, 2019 (actual)
NCT01517477One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma SubjectsNot phased (device or behavioral study)Completed2012-01Oct 18, 2019 (actual)
NCT01252849Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma SubjectsNot phased (device or behavioral study)Completed2010-12Oct 8, 2019 (actual)
NCT01444105Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser TrabeculoplastyNot phased (device or behavioral study)Completed2011-09Apr 9, 2019 (actual)
NCT01455467Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract SurgeryNot phased (device or behavioral study)Completed2011-09Oct 18, 2019 (actual)
NCT01461291Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract SurgeryNot phased (device or behavioral study)CompletedJan 16, 2012Aug 4, 2017 (actual)
NCT01461278Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract SurgeryNot phased (device or behavioral study)CompletedDec 22, 2011Mar 13, 2019 (actual)
NCT01841450Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract SurgeryNot phased (device or behavioral study)Unknown status (ClinicalTrials.gov)2013-072021-08 (actual)
NCT04624685iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval StudyNot listedUnknown status (ClinicalTrials.gov)Jan 15, 2020Jan 20, 2021 (actual)
NCT00674661Corneal Collagen Cross-Linking for Ectasia (CXL)Phase 3Completed2007-122011-11 (actual)
NCT01643226Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With KeratoconusPhase 3Completed2012-072015-07 (actual)
NCT00647699Corneal Collagen Cross-linking for Progressive KeratoconusPhase 3Completed2007-122011-04 (actual)
NCT00925041Clinical Evaluation of the Vedera KXS for the Treatment of Spherical MyopiaNot phased (device or behavioral study)Completed2009-062011-08 (actual)
NCT01344187Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With KeratoconusPhase 3Completed2012-072015-06 (actual)
NCT01069848Feasibility Study of the Vedera KXS for Treatment of KeratoconusNot phased (device or behavioral study)Completed2010-012011-03 (actual)

FDA records (last 2 years)

Open jobs 44

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Clinical Research Associate - Multiple Levels AvailableUnited StatesOct 22, 2026Oct 23, 2026Not stated
Regional Business Manager - BrazilBrazilOct 16, 2026Oct 16, 2026Not stated
Sr. Applied Research EngineerBurlington, MA, United StatesOct 16, 2026Oct 18, 2026Not stated
Glaucoma Reimbursement LiaisonAtlanta, GA, United StatesOct 15, 2026Oct 16, 2026Not stated
Business Systems Manager-QualityAliso Viejo, CA, United StatesOct 14, 2026Oct 16, 2026Not stated
Sr. Quality Control InspectorBurlington, MA, United StatesOct 14, 2026Oct 16, 2026Not stated
Senior Supplier Quality Engineer IIBurlington, MA, United StatesOct 8, 2026Oct 16, 2026Not stated
Production Maintenance Technician IIISan Clemente, CA, United StatesOct 7, 2026Oct 16, 2026Not stated
Area Director, Interventional Glaucoma (Northeast)United StatesOct 7, 2026Oct 16, 2026Not stated
Plant Manager, Site Lead - BurlingtonBurlington, MA, United StatesOct 3, 2026Oct 16, 2026Not stated
Director, Data & BI Platforms - Onsite in Aliso Viejo, CAAliso Viejo, CA, United StatesOct 1, 2026Oct 16, 2026Not stated
Director, Systems Compliance - Onsite in Aliso Viejo, CAAliso Viejo, CA, United StatesOct 1, 2026Oct 16, 2026Not stated
Patient Access LiaisonUnited StatesSep 29, 2026Oct 16, 2026Not stated
Finance Lead, R&DAliso Viejo, CA, United StatesSep 25, 2026Oct 16, 2026Not stated
Finance Manager, Consolidations & ReportingAliso Viejo, CA, United StatesSep 25, 2026Oct 16, 2026Not stated
Manager/Sr. Manager, Labeling ComplianceAliso Viejo, CA, United StatesSep 9, 2026Oct 16, 2026Not stated
Sr. Supplier Quality Engineer IIAliso Viejo, CA, United StatesSep 3, 2026Oct 16, 2026Not stated
Senior Clinical Data ManagerUnited StatesSep 3, 2026Oct 16, 2026Not stated
Buyer IIBurlington, MA, United StatesSep 1, 2026Oct 16, 2026Not stated
Glaucoma Reimbursement LiaisonHouston, TX, United StatesAug 28, 2026Oct 16, 2026Not stated
Glaucoma Reimbursement LiaisonLos Angeles, CA, United StatesAug 28, 2026Oct 16, 2026Not stated
Leave of Absence ManagerAliso Viejo, CA, United StatesAug 26, 2026Oct 16, 2026Not stated
Sr. Quality Compliance ManagerSan Clemente, CA, United StatesAug 25, 2026Oct 16, 2026Not stated
Interventional Business ManagerUnited StatesAug 13, 2026Oct 16, 2026Not stated
Quality Engineer IISan Clemente, CA, United StatesAug 12, 2026Oct 16, 2026Not stated
Pharmaceutical/Biologics R&D Quality LeadAliso Viejo, CA, United StatesAug 11, 2026Oct 16, 2026Not stated
Sr. Regulatory Affairs SpecialistBurlington, MA, United StatesAug 7, 2026Oct 16, 2026Not stated
Sr. Engineering TechnicianSan Clemente, CA, United StatesJul 31, 2026Oct 16, 2026Not stated
Sr. Business Systems Analyst - SAP SuccessFactorsAliso Viejo, CA, United StatesJul 31, 2026Oct 16, 2026Not stated
Lead Manufacturing Technician (2nd shift)San Clemente, CA, United StatesJul 27, 2026Oct 16, 2026Not stated
Sr. Quality Engineer II / Sr. Quality Specialist IISan Clemente, CA, United StatesJul 24, 2026Oct 16, 2026Not stated
Principal Software Applications Engineer Onsite in Burlington MABurlington, MA, United StatesJul 22, 2026Oct 16, 2026Not stated
International Clinical Research DirectorSpainJul 16, 2026Oct 16, 2026Not stated
Sr. Manufacturing Engineer (Pharma) San Clemente, CASan Clemente, CA, United StatesJul 15, 2026Oct 16, 2026Not stated
Sr. Applied Research Engineer - BiomechanicsBurlington, MA, United StatesJul 15, 2026Oct 16, 2026Not stated
Cornea Reimbursement Liaison - Seattle WA, Portland OR, AlaskaSeattle, WA, United StatesJul 15, 2026Oct 16, 2026Not stated
Patient Access Liaison Director - East/Central USAliso Viejo, CA, United StatesJul 13, 2026Oct 16, 2026Not stated
Cornea Reimbursement Liaison - Arizona | New Mexico | Reno, NV | Sacramento, CAPhoenix, AZ, United StatesJun 26, 2026Oct 16, 2026Not stated
Customer Service Representative IIIAliso Viejo, CA, United StatesJun 11, 2026Oct 16, 2026Not stated
Manufacturing Engineer IISan Clemente, CA, United StatesJun 9, 2026Oct 16, 2026Not stated
Sr. Scientist - Small MoleculeAliso Viejo, CA, United StatesMay 7, 2026Oct 16, 2026Not stated
Manager, Quality - QC AnalyticalSan Clemente, CA, United StatesMay 1, 2026Oct 16, 2026Not stated
Sr. Scientist II, Biologics Onsite in Aliso ViejoAliso Viejo, CA, United StatesApr 28, 2026Oct 16, 2026Not stated
Sr. Software/Cloud/Web Application Developer - Onsite in Burlington, MABurlington, MA, United StatesMar 31, 2026Oct 16, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Glaukos on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback